Symbicort or budesonide and formoterol fumarate dihydrate is used for the long-term maintenance treatment of patients with asthma. Budesonide reduces inflammation in the patientâs body, and formoterol relaxes the muscles in the patientâs airways in order to improve breathing.our doctor will not recommend you to buy Symbicort if you are less than 12 years of age. Some mild side effects associated with Symbicort include headache, back pain, a stuffy nose, changes in the voice, joint or muscle pain, nausea, diarrhea, upset stomach, and vomiting.
Barracuda Networks filed its IPO on Oct 1, 2013. The stock is listed as CUDA on the . The company did not officially go public until Nov 06, 2013, when it offered 4.14M shares at $18 per share. With a total offer amount of $74.5M, Barracuda Networks's IPO was about the same size as the average IPO.
Barracuda Networks, Inc. (NYSE: CUDA), a leading provider of cloud-enabled security and data protection solutions, today announced that it will report its financial results for the fourth quarter and fiscal year ended February 28, 2017, following the close of the market on Monday, April 17, 2017.